Business
Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update
First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with KRAS/NRAS-mutated Metastatic Colorectal Cancer (mCRC) Introduced full
About this update from Cardiff Oncology, Inc.
[{"type":"text","content":"First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with KRAS/NRAS-mutated Metastatic Colorectal Cancer (mCRC)\nIntroduced full membership of Scientific Advisory Board (SAB)\nAnnounced appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer\nCash, cash equivalents, and short-term investments of approximately $97 million as of March 31, 2023, projected runway into 2025\nSAN DIEGO, May 4, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced financial results for the first-quarter ended March 31, 2023, and provided a business update.\n\n \n \n \n \n \n \n\n \n\"We are delighted to have dosed the first patient in our Phase 2 ONSEMBLE trial. This randomized trial will evaluate the efficacy of onvansertib combined with standard of care in patients with KRAS/NRAS-mutated mCRC, who historically have limited treatment options,\" said Mark Erlander, PhD, Chief Executive Officer of Cardiff Oncology. \"In addition, we are excited to have appointed Fairooz Kabbinavar, MD, FACP, as our new Chief Medical Officer, who brings deep expertise in the treatment of patients with CRC as well as expertise in using bevacizumab in the clinical setting. We believe Dr. Kabbinavar adds significant value to our clinical development program for onvansertib. We also formally introduced the full membership of our Scientific Advisory Board, a group of highly esteemed oncology experts who are providing a diverse range of insights that strengthen our clinical programs.\"\nUpcoming potential milestones\nMetastatic pancreatic ductal adenocarcinoma (mPDAC) data readout from Phase 2 trial expected in mid-2023Small cell lung cancer (SCLC) data readout from investigator-initiated (with UPMC) Phase 2 trial expected in mid-2023Triple negative breast cancer (TNBC) data readout from investigator-initiated (with Dana-Farber Cancer Institute) Phase 1b/2 trial expected in the fourth-quarter of 2023 or first-quarter of 2024mCRC randomized data readout from Phase 2 ONSEMBLE trial expected in the second-half of 2024Company Highlights for the quarter ended March 31, 2023\nAnnounced the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer. ...